ליקסומיה 20 מק"ג - Lyxumia 20 mcg

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

××× ×× ×× × ××¡×¤××

×××§×¡×××× 10 ××§"× - Lyxumia 10 mcg

×§×××¦× ×¤×¨××§××××××ª (ATC4)

A10BJ
Glucagon-like peptide-1 (GLP-1) analogues

××¨××× ×¤×¢×× (ATC5)

Â

Lixisenatide 20 MCG / 0.2 ML âA10BJ03

×¦××¨×ª ××ª×

×ª×ª-×¢××¨× - S.C

×¦××¨×ª ××× ××

×ª×××¡× ××××¨×§×, SOLUTION FOR INJECTION
××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××

××ª××××

For the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

15/01/2015

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××
×××¤×× ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××: ×. ×¢×¨× HbA1c 7.5% ×××¢×× ××¢×× ×× ×¢× ××× ××××: 1. ×¢× BMI ××¢×¨× 28 ×××¢××; 2. ×¢× BMI ××¢×¨× 25 ×××¢××, ×××××× ×××× ×××××× â ××××ª ×× ××××××ª, ×××× ×¡×¨××¨×××¡×§×××¨××ª, ××××ª ×××× ××¨×× ××ª, ××××ª ××× ×× ×¤×¨××¤×¨××ª - (PVD - Peripheral vascular disease). ×. ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡; ×. ××× × ×¡××××× ××× ×¡×¤××§× ×××××ª××ª (×§×¨×××× ×× ××¢× 1.5); ×. ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª, ××× ××¤×××ª.	01/03/2021	×× ×××§×¨×× ××××××	LIRAGLUTIDE, LIXISENATIDE, DULAGLUTIDE, EXENATIDE	×¡×××¨×ª ×¡×× 2, Diabetes
××××¤×× ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××: 1. ××¢×× ×× ×¢× ××× ××××: ×. BMI ××¢× 30 ×-HbA1c ××¢× 7.5%; ×. BMI ××× 28-30 ×-HbA1c ××¢× 9.0%; ×. BMI ××× 28-30 ×-HbA1c ××× 7.5 ×-9.0% ×××××× ×××× ×××××× â ××××ª ×× ××××××ª, ×××× ×¡×¨××¨×××¡×§×××¨××ª, ××××ª ×××× ××¨×× ××ª. 2. ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡; 3. ××× × ×¡××××× ××× ×¡×¤××§× ×××××ª××ª (×§×¨×××× ×× ××¢× 1.5); 4. ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª, ××× ××¤×××ª.	11/01/2018	×× ×××§×¨×× ××××××	LIRAGLUTIDE, LIXISENATIDE, DULAGLUTIDE, EXENATIDE	×¡×××¨×ª ×¡×× 2, Diabetes
×××¤×× ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××: 1. ××¢×× ×× ×¢× ××× ××××: ×. BMI ××¢× 30 ×-HbA1c ××¢× 7.5; ×. BMI ××× 28-30 ×-HbA1c ××¢× 9.0; 2. ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡; 3. ××× × ×¡××××× ××× ×¡×¤××§× ×××××ª××ª (×§×¨×××× ×× ××¢× 1.5); 4. ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª, ××× ××¤×××ª.	15/01/2015	×× ×××§×¨×× ××××××	LIRAGLUTIDE, LIXISENATIDE, DULAGLUTIDE, EXENATIDE	×¡×××¨×ª ×¡×× 2, Diabetes

×©××××© ××¡×

××¡××¨×ª ××××× ××¡×

××ª×¨××¤××ª ××× ×ª× × ××××¤×× ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××:

×. ×¢×¨× HbA1c 7.5% ×××¢×× ××¢×× ×× ×¢× ××× ××××:

1. ×¢× BMI ××¢×¨× 28 ×××¢××;

2. ×¢× BMI ××¢×¨× 25 ×××¢××, ×××××× ×××× ×××××× â ××××ª ×× ××××××ª, ×××× ×¡×¨××¨×××¡×§×××¨××ª, ××××ª ×××× ××¨×× ××ª, ××××ª ××× ×× ×¤×¨××¤×¨××ª - (PVD - Peripheral vascular disease).

×. ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡;

×. ××× × ×¡××××× ××× ×¡×¤××§× ×××××ª××ª (×§×¨×××× ×× ××¢× 1.5);

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

Â

×¢××× ××¨××¤× 07.12.2014

Â

×¢××× ××¦×¨××	Â ×¢××× ××¦×¨×× 07.12.2014 ×××¨×××ª ×©××××© 03.07.2014

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
×××§×¡×××× 20 ××§"× ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY
×©× ××¢× ××¨××©××	SANOFI - AVENTIS ISRAEL LTD
×¨××©×××	×ª××¨×× ×××©×: 2/2013. ×¨××©××× ××ª××¨××:
×ª××¨×× ×¢×××× ×××¨××	07/11/2021

××××¢ × ××¡×£ ××¨××¤×××

××¦×¤××× ×××××¢ ×××¨×× ××¨××¤××× ××© ××××× ×¡ ×××©××× ×. ×× ××× × ×¨×©×× ××× ×¡ ×××¨×©×× ××¨××¤××× ××× ×©× ××§×¦××¢××ª ×¨×¤×××××.

Lyxumia SPC 07 12 14

Lyxumia_10mcg

××××¨××

××¦×¤××× ×××××¢ ×××¨×× ××¨××¤××× ××© ××××× ×¡ ×××©××× ×. ×× ××× × ×¨×©×× ××× ×¡ ×××¨×©×× ××¨××¤××× ××× ×©× ××§×¦××¢××ª ×¨×¤×××××.

ליקסומיה 20 מק"ג - Lyxumia 20 mcg

ויקיתרופות